• If you are wondering whether DENTSPLY SIRONA stock is starting to look interesting at current levels, its recent price and valuation signals give you a lot to think about.
• The share price sits at US$10.96 after a 6.7% decline over the last week, a 4.9% decline over the last month and a 28.5% decline over the last year, which may change how you view both its risk and potential reward.
• Recent coverage around DENTSPLY SIRONA has focused on its position within the medical equipment space and how investors are reacting to the stock's long term share price record, including a 70.9% decline over three years and an 81.7% decline over five years. This backdrop helps frame whether current pricing reflects cautious sentiment or an opportunity that the market is overlooking.
• DENTSPLY SIRONA currently records a valuation score of 6/6 on Simply Wall St's checks, so next up is a breakdown of what those methods say about the stock's value and how you can go a step further to interpret valuation in a more useful way by the end of this article.

Approach 1: DENTSPLY SIRONA Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes projected future cash flows that a company may generate and discounts them back to today to estimate what the business could be worth now.

For DENTSPLY SIRONA, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow stands at about $114.5 million. Analyst inputs and Simply Wall St extrapolations point to free cash flow reaching $564.2 million in 2035, with intermediate projections such as $234.5 million in 2026 and $386 million in 2029.

Discounting these projected cash flows, the DCF model arrives at an estimated intrinsic value of about $31.20 per share. Compared with the recent share price of $10.96, this implies a 64.9% discount, which indicates that the stock appears materially undervalued on this model alone.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests DENTSPLY SIRONA is undervalued by 64.9%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: DENTSPLY SIRONA Price vs Sales

For companies where earnings can be volatile or negative, the P/S ratio is often a useful cross check because it compares what you pay for the stock with the revenue the business generates. Investors usually accept a higher P/S ratio if they expect stronger growth and lower risk, and look for a lower P/S ratio when growth expectations are modest or risks are higher.

DENTSPLY SIRONA currently trades on a P/S ratio of 0.60x. This sits well below the Medical Equipment industry average P/S of 2.75x and the peer group average of 3.70x. At face value, that gap suggests the market is pricing DENTSPLY SIRONA at a discount to many other companies in the same space.

Simply Wall St’s Fair Ratio is a tailored benchmark for the P/S multiple, set at 1.20x for DENTSPLY SIRONA, based on factors such as its growth profile, industry, profit margins, market capitalization and company specific risks. Because it incorporates these elements directly, the Fair Ratio can be more informative than a simple comparison with peers or the broad industry, which may have very different characteristics. Comparing the current P/S of 0.60x with the Fair Ratio of 1.20x indicates the stock is trading at a sizeable discount.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your DENTSPLY SIRONA Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as simple story driven forecasts that let you describe how you think DENTSPLY SIRONA will perform, connect that story to revenue, earnings and margin assumptions on Simply Wall St's Community page, translate those assumptions into a Fair Value, then compare that Fair Value with the current price to judge whether the stock looks attractive or stretched. The Narrative updates automatically when fresh news or earnings arrive. For example, one investor might build a cautious DENTSPLY SIRONA Narrative that lines up with a Fair Value around US$10.00 and expectations for profit margins near 3.0% and earnings of about US$108.9m by 2029. Another might build a more optimistic Narrative anchored to a Fair Value near US$18.00 with margins around 6.2% and earnings of roughly US$240.5m. This gives you a clear, side by side view of how different stories lead to different valuations.

For DENTSPLY SIRONA, we will make it really easy for you with previews of two leading DENTSPLY SIRONA Narratives:

Fair value: US$45.50 per share

Current price vs this fair value: about 75.9% below that narrative fair value

Modeled revenue growth rate: 192.63%

• Frames DENTSPLY SIRONA as a durability story, tied to recurring dental procedures and long equipment replacement cycles rather than short term trading moves.
• Highlights the role of consumables and service revenue in supporting steadier cash flows, while gradual technology upgrades and compatibility help retain dental practices.
• Argues that the appeal of the stock rests on resilience, disciplined execution and practice level economics, not rapid expansion or headline driven growth.

Fair value: US$10.00 per share

Current price vs this fair value: about 9.6% above that narrative fair value

Modeled revenue growth rate: 7.07%

• Emphasizes risks from rising competition, cost pressures and weaker pricing power, which could keep revenue growth muted and margins under strain.
• Points to governance history, potential legal and regulatory costs and consolidation among large dental groups as ongoing headwinds for earnings.
• Suggests the stock price already assumes a recovery in profitability and a relatively high future P/E, so any misstep on execution could leave limited room for error.

These two Narratives give you a clear spread of assumptions to test against your own view of DENTSPLY SIRONA, whether you lean more toward the resilience story or the caution around execution and margin pressure.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for DENTSPLY SIRONA on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for DENTSPLY SIRONA? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.